{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:36:10Z","timestamp":1759178170050},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/jcp.0b013e3182408fc8","type":"journal-article","created":{"date-parts":[[2011,12,24]],"date-time":"2011-12-24T16:48:34Z","timestamp":1324745314000},"page":"110-113","source":"Crossref","is-referenced-by-count":4,"title":["Ketoconazole-Associated Preferential Increase in Dopamine D2 Receptor Occupancy in Striatum Compared to Pituitary In Vivo"],"prefix":"10.1097","volume":"32","author":[{"given":"Christopher","family":"Reist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ylva","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jogeshwar","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Gripeos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Augusta","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mercolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vural","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-18-20210128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00004714-200112000-00011","article-title":". Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and C-A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine.","volume":"21","author":"Ozdemir","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R3-18-20210128","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","article-title":". Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.","volume":"147","author":"Scordo","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"R5-18-20210128","first-page":"1","article-title":"Crossing the blood-brain-barrier: integration of scientific innovation with socio-ethical reflection.","volume":"24","author":"Ozdemir","year":"2007","journal-title":"Psychiatric Times"},{"key":"R6-18-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s002130050726","article-title":"Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat.","volume":"139","author":"Aravagiri","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"R7-18-20210128","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","article-title":". The brain penetration of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.","volume":"7","author":"Wang","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"R8-18-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/dmd.104.001230","article-title":". The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A1B knockout mouse model.","volume":"33","author":"Doran","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"R9-18-20210128","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.brainres.2005.03.018","article-title":". Lack of cataleptogenic potentiation with non-imidazole H(3) receptor antagonists reveals potential drug-drug interactions between imidazole-based H(3) receptor antagonists and antipsychotic drugs.","volume":"1045","author":"Zhang","year":"2005","journal-title":"Brain Res"},{"key":"R10-18-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0091270004269705","article-title":". Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.","volume":"45","author":"Kharasch","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"R11-18-20210128","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1067\/mcp.2002.124080","article-title":". Effect of St Johns wort on the pharmacokinetics of fexofenadine.","volume":"71","author":"Wang","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"R16-18-20210128","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/jps.20963","article-title":"Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).","volume":"96","author":"Gupta","year":"2007","journal-title":"J Pharm Sci"},{"issue":"2","key":"R19-18-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4.","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R24-18-20210128","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/j.1539-6924.2010.01517.x","article-title":"Responsible innovation: a pilot study with the U.K. Engineering and Physical Sciences Research Council.","volume":"30","author":"Owen","year":"2010","journal-title":"Risk Anal"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201202000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:17:29Z","timestamp":1618035449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201202000-00018"}},"subtitle":["Role for Drug Transporters?"],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3182408fc8","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}